Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0000950170-25-068038
Filing Date
2025-05-09
Accepted
2025-05-09 16:15:04
Documents
1
Period of Report
2025-05-08

Document Format Files

Seq Description Document Type Size
1 4 ownership.html 4  
1 4 ownership.xml 4 3615
  Complete submission text file 0000950170-25-068038.txt   5032
Mailing Address 26 LANDSDOWNE STREET CAMBRIDGE MA 02139
Business Address 26 LANDSDOWNE STREET CAMBRIDGE MA 02139 617-651-8851
Fulcrum Therapeutics, Inc. (Issuer) CIK: 0001680581 (see all company filings)

EIN.: 474839948 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address C/O FULCRUM THERAPEUTICS, INC. 26 LANDSDOWNE STREET CAMBRIDGE MA 02139
Business Address
Tourangeau Greg (Reporting) CIK: 0001916566 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-38978 | Film No.: 25930597